Cargando…

PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease

The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling to predict the effect of liver disease (LD) on the pharmacokinetics (PK) of dexamethasone (DEX) in the treatment of COVID-19. A whole-body PBPK model was created to simulate 100 adult individuals aged 18–60 year...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montanha, Maiara Camotti, Cottura, Nicolas, Booth, Michael, Hodge, Daryl, Bunglawala, Fazila, Kinvig, Hannah, Grañana-Castillo, Sandra, Lloyd, Andrew, Khoo, Saye, Siccardi, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832977/ https://www.ncbi.nlm.nih.gov/pubmed/35153785 http://dx.doi.org/10.3389/fphar.2022.814134

Ejemplares similares

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
por: Grañana-Castillo, Sandra, et al.
Publicado: (2022)

Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2021)

Correction to: Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2022)

Drug–Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives
por: Cottura, Nicolas, et al.
Publicado: (2022)

Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
por: Stader, Felix, et al.
Publicado: (2018)

Correction to: Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling
por: Kinvig, Hannah, et al.
Publicado: (2022)

Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling
por: Kinvig, Hannah, et al.
Publicado: (2022)

A Workflow for Global Sensitivity Analysis of PBPK Models
por: McNally, Kevin, et al.
Publicado: (2011)

Analysis of biomarker utility using a PBPK/PD model for carbaryl
por: Phillips, Martin B., et al.
Publicado: (2014)

PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer’s disease
por: Bloomingdale, Peter, et al.
Publicado: (2022)

Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring
por: Zapke, Sonja E., et al.
Publicado: (2021)

SimRFlow: An R-based workflow for automated high-throughput PBPK simulation with the Simcyp(®) simulator
por: Khalidi, Hiba, et al.
Publicado: (2022)

PBPK modeling to evaluate maximum tolerated doses: A case study with 3-chloroallyl alcohol
por: Conolly, Rory P., et al.
Publicado: (2023)

PBPK-based dose finding for sildenafil in pregnant women for antenatal treatment of congenital diaphragmatic hernia
por: Macente, Julia, et al.
Publicado: (2023)

Semi-PBPK Modeling and Simulation to Evaluate the Local and Systemic Pharmacokinetics of OC-01(Varenicline) Nasal Spray
por: Wu, Xiaofei, et al.
Publicado: (2022)

Addressing Adherence Using Genotype-Specific PBPK Modeling—Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels
por: Dickschen, Kristin J. R., et al.
Publicado: (2017)

Hepatic Cytochrome P450 Abundance and Activity in the Developing and Adult Göttingen Minipig: Pivotal Data for PBPK Modeling
por: Buyssens, Laura, et al.
Publicado: (2021)

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
por: Grzegorzewski, Jan, et al.
Publicado: (2022)

Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends
por: Abouir, Kenza, et al.
Publicado: (2021)

A compatibility evaluation between the physiologically based pharmacokinetic (PBPK) model and the compartmental PK model using the lumping method with real cases
por: Ryu, Hyo-jeong, et al.
Publicado: (2022)

The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis
por: Duwal, Sulav, et al.
Publicado: (2019)

Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis
por: Ayyar, Vivaswath S., et al.
Publicado: (2022)

Refinement and calibration of a human PBPK model for the plasticiser, Di-(2-propylheptyl) phthalate (DPHP) using in silico, in vitro and human biomonitoring data
por: McNally, Kevin, et al.
Publicado: (2023)

A PBPK Model of Ternary Cyclodextrin Complex of ST-246 Was Built to Achieve a Reasonable IV Infusion Regimen for the Treatment of Human Severe Smallpox
por: Zhang, Zhiwei, et al.
Publicado: (2022)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz
por: Chetty, Manoranjenni, et al.
Publicado: (2018)

Development, Testing, Parameterisation and Calibration of a Human PBPK Model for the Plasticiser, Di-(2-propylheptyl) Phthalate (DPHP) Using in Silico, in vitro and Human Biomonitoring Data
por: McNally, Kevin, et al.
Publicado: (2021)

Development, testing, parameterisation, and calibration of a human PBPK model for the plasticiser, di-(2-ethylhexyl) terephthalate (DEHTP) using in silico, in vitro and human biomonitoring data
por: McNally, Kevin, et al.
Publicado: (2023)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability
por: Chetty, Manoranjenni, et al.
Publicado: (2014)

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach
por: Dickinson, Laura, et al.
Publicado: (2014)

SeDeM tool-driven full factorial design for osmotic drug delivery of tramadol HCl: Formulation development, physicochemical evaluation, and in-silico PBPK modeling for predictive pharmacokinetic evaluation using GastroPlus™
por: Saleem, Muhammad Talha, et al.
Publicado: (2022)

Using available in vitro metabolite identification and time course kinetics for β-chloroprene and its metabolite, (1-chloroethenyl) oxirane, to include reactive oxidative metabolites and glutathione depletion in a PBPK model for β-chloroprene
por: Campbell, J. L., et al.
Publicado: (2023)

Metabolomics Based Profiling of Dexamethasone Side Effects in Rats
por: Malkawi, Abeer K., et al.
Publicado: (2018)

Allergic Asthma-Induced Cognitive Impairment is Alleviated by Dexamethasone
por: Ren, Mengli, et al.
Publicado: (2021)

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter
por: Moss, Darren M., et al.
Publicado: (2015)

IFN-β mediates the anti-osteoclastic effect of bisphosphonates and dexamethasone
por: Kalkar, Prajakta, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

PBPK perspective on alternative CYP3A4 inducers for rifampin
por: Chen, Kuan‐Fu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ost2i4b6ie9t7ljcav1vi3se4c